You are here

Regeneron

Regeneron’s linvoseltamab shows early and durable response in pre-treated MM

Regeneron’s linvoseltamab shows early and durable response in pre-treated MM

Clinical Trials Arena

clinical trials

bispecific antibodies

Flag link:

FDA Decisions 2023: Sandoz, Gilead Sciences and More

FDA Decisions 2023: Sandoz, Gilead Sciences and More

BioSpace

Gilead Sciences

Revance Therapeutics

Delcath Systems

Galera Therapeutics

Flag link:

Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products

Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products

BioSpace

Flag link:

Regeneron Expands Eylea’s Label with High-Dose Approval

Regeneron Expands Eylea’s Label with High-Dose Approval

BioSpace

Flag link:

Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease

Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease

BioSpace

Flag link:

FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron

FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron

BioSpace

Revance Therapeutics

fibrodysplasia ossificans progressiva

cervical dystonia

Huntington's disease

Flag link:

Regeneron's high-dose Eylea shows staying power as company awaits FDA decision

Regeneron's high-dose Eylea shows staying power as company awaits FDA decision

Fierce Pharma

age-related macular degeneration

Flag link:

Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration

Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration

Fierce Biotech

Decibel Therapeutics

Flag link:

Regeneron expects FDA decision on higher-dose Eylea this year

Regeneron expects FDA decision on higher-dose Eylea this year

Reuters

Flag link:

Moderna, Regeneron post solid earnings, eye a strong finish to 2023

Moderna, Regeneron post solid earnings, eye a strong finish to 2023

Medical Marketing and Media

Moderna Therapeutics

Flag link:

Regeneron rethinks CD28 bispecific R&D plan after 2 patients die

Regeneron rethinks CD28 bispecific R&D plan after 2 patients die

Fierce Biotech

prostate cancer

clinical trials

bispecific antibodies

Flag link:

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

BioSpace

fibrodysplasia ossificans progressiva

Santhera Pharmaceuticals

Flag link:

Scratching the surface of the urticaria pipeline

Scratching the surface of the urticaria pipeline

EP Vantage

chronic urticaria

Celldex Therapeutics

Flag link:

Dupixent goes back-to-back as top Rx, OTC pharma brand in June

Dupixent goes back-to-back as top Rx, OTC pharma brand in June

Medical Marketing and Media

Flag link:

Is Regeneron's Stock in Trouble After This FDA Rejection?

Is Regeneron's Stock in Trouble After This FDA Rejection?

Motley Fool

Flag link:

Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups

Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups

Fierce Pharma

Flag link:

Aslan sells Japanese rights to would-be Dupixent rival for $12M

Aslan sells Japanese rights to would-be Dupixent rival for $12M

Fierce Biotech

Flag link:

Dupixent reclaims throne as top Rx, OTC pharma brand in May

Dupixent reclaims throne as top Rx, OTC pharma brand in May

Medical Marketing and Media

DTC advertising

Flag link:

ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma

ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma

Fierce Biotech

advanced melanoma

Flag link:

Pages